-
Codiak BioSciences Inc (NASDAQ: CDAK) announced new preclinical data from its pan beta-coronavirus vaccine program.
-
The data demonstrate the potential for the vaccine candidate to induce cross-neutralizing antibody protection against multiple strains and an antigen-specific & immune response against structurally conserved regions of various coronavirus variants.
-
Preclinical data showed a durable antibody response lasting at least eight months in a mouse model.
-
Read Next: Codiak BioSciences' Precision Medicine Approach Shows Potent Activity In Cancer Models.
-
Induction of mucosal immune responses in vaccinated mice was equivalent to responses in humans immunized with an mRNA vaccine and induction of lung resident memory CD4 and CD8 T cells when administered intranasally.
-
Data also exhibited 100% survival and minimal evidence of infection in lung tissues upon challenge with the Delta variant.
-
The engineered exosome-based vaccine candidate is derived from Codiak's exoVACC platform that can deliver antigens and adjuvants simultaneously and selectively to the same antigen-presenting cells.
-
Price Action: CDAK shares closed at $3.88 on Wednesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.